JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


J. Biol. Chem., Vol. 281, Issue 13, 99906, March 31, 2006
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrow Papers Of The Week
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Activation of a Tumor Suppressor{diamondsuit}

More than a decade after p53 was recognized as a major tumor suppressor, the p53 homolog p73beta was identified. Like p53, p73beta can induce cell cycle arrest and apoptosis in response to DNA damage or after the activation of selected oncogenes. However, p73beta only activates the transcription of a subset of p53-responsive genes, and it interacts with different viral oncoproteins, indicating that despite their similarities, the two proteins have distinct cellular functions. Because of these differences it is important to understand the mechanisms that govern the regulation of both tumor suppressors.Go


Figure 1
p19ras co-localizes with p73beta.

Using the yeast two-hybrid screening method, Mi-Hee Jeong and colleagues have now identified a novel p73beta-binding protein. The protein, p19ras, is an alternative splicing product of the proto-oncogene H-ras. When bound to p73beta, p19ras stimulates its transcriptional activity. Jeong et al. also discovered that when p19ras binds to MDM2, a known repressor of p73 and p53 transcriptional activity, it inhibits MDM2 association with p73beta thereby abolishing MDM2-mediated transcriptional repression of p73beta. If p19ras has a similar effect on p53, this would suggest that an alternatively spliced product of a prominent oncogene may activate tumor suppressor pathways, an important finding for the field of cancer biology.

FOOTNOTES

{diamondsuit} See referenced article, J. Biol. Chem. 2006, 281, 8707-8715 Back



Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
Related Collections
Right arrow Papers Of The Week
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2006 by the American Society for Biochemistry and Molecular Biology.